Asahi Life Asset Management CO. LTD. Has $601,000 Holdings in Eli Lilly and Company (NYSE:LLY)

Asahi Life Asset Management CO. LTD. lifted its holdings in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 65.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,860 shares of the company’s stock after purchasing an additional 735 shares during the period. Asahi Life Asset Management CO. LTD.’s holdings in Eli Lilly and were worth $601,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Insight Inv LLC bought a new position in Eli Lilly and during the second quarter worth $26,000. Castle Wealth Management LLC bought a new position in Eli Lilly and during the second quarter worth $28,000. Horan Securities Inc. raised its stake in Eli Lilly and by 96.0% during the second quarter. Horan Securities Inc. now owns 98 shares of the company’s stock worth $32,000 after buying an additional 48 shares during the last quarter. Cypress Capital Management LLC WY raised its stake in Eli Lilly and by 300.0% during the second quarter. Cypress Capital Management LLC WY now owns 100 shares of the company’s stock worth $32,000 after buying an additional 75 shares during the last quarter. Finally, New Millennium Group LLC bought a new position in Eli Lilly and during the second quarter worth $34,000. Institutional investors and hedge funds own 82.13% of the company’s stock.

Insider Buying and Selling at Eli Lilly and

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 49,089 shares of the business’s stock in a transaction dated Friday, December 2nd. The shares were sold at an average price of $372.88, for a total value of $18,304,306.32. Following the transaction, the insider now directly owns 102,948,810 shares in the company, valued at $38,387,552,272.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 49,089 shares of the business’s stock in a transaction that occurred on Friday, December 2nd. The shares were sold at an average price of $372.88, for a total value of $18,304,306.32. Following the sale, the insider now owns 102,948,810 shares of the company’s stock, valued at $38,387,552,272.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Acquisition Corp Kearny purchased 29,992,668 shares of the stock in a transaction dated Wednesday, November 30th. The stock was acquired at an average cost of $12.50 per share, for a total transaction of $374,908,350.00. Following the transaction, the insider now owns 100 shares of the company’s stock, valued at $1,250. The disclosure for this purchase can be found here. Insiders have sold a total of 120,141 shares of company stock worth $44,151,279 over the last three months. 0.12% of the stock is currently owned by insiders.

Eli Lilly and Stock Up 0.8 %

Eli Lilly and stock traded up $2.70 during midday trading on Wednesday, hitting $349.09. 316,923 shares of the stock were exchanged, compared to its average volume of 2,408,808. Eli Lilly and Company has a 52-week low of $231.87 and a 52-week high of $384.44. The stock has a market capitalization of $331.70 billion, a price-to-earnings ratio of 52.01, a price-to-earnings-growth ratio of 2.12 and a beta of 0.36. The business’s 50-day moving average price is $361.80 and its 200-day moving average price is $338.46. The company has a quick ratio of 0.88, a current ratio of 1.13 and a debt-to-equity ratio of 1.39.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings results on Tuesday, November 1st. The company reported $1.98 earnings per share for the quarter, topping the consensus estimate of $1.97 by $0.01. Eli Lilly and had a net margin of 20.63% and a return on equity of 80.80%. The business had revenue of $6.94 billion for the quarter, compared to analysts’ expectations of $6.91 billion. On average, research analysts expect that Eli Lilly and Company will post 7.77 EPS for the current fiscal year.

Eli Lilly and Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 10th. Shareholders of record on Wednesday, February 15th will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 1.29%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.98. The ex-dividend date of this dividend is Tuesday, February 14th. Eli Lilly and’s payout ratio is presently 58.86%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and from $380.00 to $400.00 in a research note on Wednesday, December 14th. Guggenheim lifted their target price on shares of Eli Lilly and from $399.00 to $401.00 and gave the stock a “buy” rating in a research note on Wednesday, December 7th. Cowen lifted their price target on shares of Eli Lilly and from $390.00 to $430.00 in a research note on Monday, December 5th. Cowen lifted their price target on shares of Eli Lilly and from $390.00 to $430.00 and gave the company an “outperform” rating in a research note on Monday, December 5th. Finally, Wells Fargo & Company lifted their price target on shares of Eli Lilly and from $365.00 to $375.00 and gave the company an “equal weight” rating in a research note on Thursday, December 8th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $384.11.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.